Safety of azithromycin in infants under six months of age in Niger: A community randomized trial.

ABSTRACT:

Background

Mass azithromycin distribution reduces under-5 child mortality. Trachoma control programs currently treat infants aged 6 months and older. Here, we report findings from an infant adverse event survey in 1-5 month olds who received azithromycin as part of a large community-randomized trial in Niger.

Methods and principal findings

Active surveillance of infants aged 1-5 months at the time of treatment was conducted in 30 randomly selected communities from within a large cluster randomized trial of biannual mass azithromycin distribution compared to placebo to assess the potential impact on child mortality. We compared the distribution of adverse events reported after treatment among azithromycin-treated versus placebo-treated infants. From January 2015 to February 2

SUBMITTER: Oldenburg CE 

PROVIDER: S-EPMC6258425 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature